Epidemiology, Staging, and Management of Multiple Myeloma
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index; 21 of the 61 sources its claims cite were checked for support.
Abstract
Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the global proportion). Incidence has risen by 126% globally and over 40% in the US since 1990, while global mortality has risen by 94% and US mortality has fallen by 18%. The 5 year survival in the US has more than doubled over the past decades with the introduction of new targeted therapies and transplant techniques. Risk factors for MM include age (average age of diagnosis is 69), race (African Americans are over double as likely to be diagnosed), sex (men are at a 1.5× risk), and family history. Diagnosis includes serum or urine electrophoresis and free light-chain assay but requires bone marrow biopsy. It is distinguished from smoldering myeloma and monoclonal gammopathy of undetermined significance by a high (>3 g/dL) level of M-protein (monoclonal light chains) and the presence of CRAB (Hypercalcemia, Renal failure, Anemia, Bone pain) symptoms, which include hypercalcemia, renal failure, anemia, and bone pain, suggesting an end-organ damage. International staging system staging involves beta 2 microglobulin and albumin levels, while the revised system considers prognostic factors such as lactate dehydrogenase levels and chromosomal abnormalities. Front-line management includes induction regimen, maintenance therapy and hematopoietic cell transplantation for eligible patients and bisphosphonates or bone-stimulating agents for the prevention of skeletal events. Treatment for relapsed disease includes newly approved monoclonal antibodies like the CD38-targeting daratumumab, proteasome inhibitors, immunomodulating agents, and investigational therapies such as B cell maturation antigen Chimeric antigen receptor T cells.
Overview
CoChat Summary
## TL;DR
This 2021 review summarizes the epidemiology, staging, diagnosis, and management of multiple myeloma, emphasizing that incidence has risen while survival has improved with newer therapies and transplant techniques. It also highlights the major risk groups, current staging systems, and common first-line and relapsed-disease treatment approaches.
## Key findings
- Global MM burden was estimated at 160,000 cases in 2018 and 106,000 deaths in 2018; MM accounted for 0.9% of all cancer diagnoses and 1.1% of all cancer deaths.
- From 1990 to 2016, global incidence increased by 126% and global deaths increased by 94%; in the US, incidence rose by 143% since 1975, while mortality fell and 5-year survival increased from 23.7% in 1976 to 53.9% in 2016.
- Risk is higher in older adults (median diagnosis age 69 in the US), men (about 1.5× higher risk globally), and African Americans (incidence 16.5/100,000 in African American men and 12.0/100,000 in African American women, versus 8.2 and 5.0 in Caucasians).
- In an international clinical trial with 3,060 participants, 5-year survival by revised ISS stage was 82% for stage I, 62% for stage II, and 40% for stage III.
## Methods
- Narrative review article describing the “latest review” of MM; the paper states that an extensive literature search was done.
- Synthesizes epidemiologic data (e.g., GLOBOCAN, SEER), staging systems (ISS, DSS, revised ISS), diagnostic criteria, and treatment evidence from cited trials and studies.
- Main analysis is descriptive and integrative rather than experimental, comparing published incidence, mortality, risk-factor, staging, and treatment results.
## Limitations
- The paper does not report a systematic review method, search strategy, or inclusion/exclusion criteria; this is evident from the text (descriptive review), not stated as a limitation by the authors.
- The evidence base is largely observational and from cited studies/trials across different settings, so direct causal inference is limited; this is evident from the text.
- Not stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Map showing the estimated age-standardized incidence rates per 100,000 (world) in 2018 of multiple myeloma (MM) for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/53cda705514b4aeea933ce5143d2fbf3/epidemiology-staging-and-management-of-multiple-myeloma-figure-1.jpg)
![Figure 2 Map showing the estimated age-standardized mortality rates per 100,000 (world) in 2018 of multiple myeloma for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/0a44533b89b8450397215c10f72e1fcc/epidemiology-staging-and-management-of-multiple-myeloma-figure-2.jpg)
![Figure 3 Graph showing the estimated cumulative risk of incidence in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/525138bbaf0842a7aaa427b870ecd122/epidemiology-staging-and-management-of-multiple-myeloma-figure-3.jpg)
![Figure 4 Graph showing the estimated number of prevalent cases (5 year) as a population in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2 Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/6e96994452ec4de28c61f038e43ff651/epidemiology-staging-and-management-of-multiple-myeloma-figure-4.jpg)
![Figure 5 Bar chart showing the 5 year age-adjusted mortality rates from 2013–2017 by age for the United States. Created with Tableau 2019.2. Data source: SEER*Explorer [11].](https://figures.cochat.ai/paper-figures/82c4eb6e362047998968d2004b611456/epidemiology-staging-and-management-of-multiple-myeloma-figure-5.jpg)
![Figure 6 Bar chart showing the United States’ 5-year age-adjusted mortality rates from 2013–2017 for all races (including Hispanics). Created with Tableau 2019.2. Data source: SEER*Explorer [11].](https://figures.cochat.ai/paper-figures/b8ccac5b620b49deb4385d0716c909bd/epidemiology-staging-and-management-of-multiple-myeloma-figure-6.jpg)

Verification
Claims the paper makes
15 Valid · 12 Not valid · 29 Not checked · 10 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“KRd instead of VRd can be used as initial therapy in patients with t(4;14), t(14;16), t(14;20), and those with ≥2 high-risk abnormalities based on the results of phase 2 studies suggesting higher complete response (CR) rates and minimal residual disease negativity rates compared with historical results using VRd [28,30,31].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Disputedcites [28] Rajkumar, 2011, Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management, Am. J. Hematol. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
- Not checked yetcites [30] Rajkumar, 2010, Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management, Am. J. Hematol. source
Checked before — its earlier verdict is held back until a new check runs.
- Not checked — no full text of the sourcecites [31] Sheng, 2017, Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials, Eur. J. Haematol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Suggested underlying factors include discrepancies in health-risk behaviors, such as smoking and alcohol consumption, and higher rates of obesity among men, though none of these risk factors have been proven in MM [9].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 2. Epidemiology > 2.3. Risk Factors
What the sources say
- Partly supportedcites [9] Cowan, 2018, Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016, JAMA Oncol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says there is a “lack of known strong risk factors for myeloma,” which supports the claim’s general caution. It does not assess smoking, alcohol consumption, or obesity individually, or identify them as explanations for higher rates among men. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The revised international staging system (RISS) combines elements of tumor burden (ISS) and disease biology [23].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.2. Staging
What the sources say
- Supportedcites [23] Palumbo, 2015, Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J. Clin. Oncol. source
The Introduction describes an ISS marker as reflecting tumour mass and identifies chromosomal abnormalities as biological features of multiple myeloma. The Discussion states that R-ISS combines ISS staging, chromosomal abnormalities and serum LDH, supporting the paraphrase. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Those undergoing HCT typically receive a triplet regimen for 3–4 months prior to stem cell collection in order to reduce tumor cell numbers in the bone marrow.”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Could not verifycites [33] Chim, 2018, Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond, Leukemia sourceExperimental — accuracy not yet measured
The 'Role of salvage ASCT' section discusses re-induction before a second transplant, and the 'Proposed treatment algorithm' section prefers triplets for relapsed myeloma. Neither addresses a typical 3–4-month triplet regimen before stem-cell collection to reduce tumor cells in the bone marrow; searches for that timing and purpose found no supporting passage. Page numbers were unavailable in our copy. (LLM, conf=0.76)
- Partly supportedcites [34] Laubach, 2016, Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group, Leukemia sourceExperimental — accuracy not yet measured
Our copy supports the general idea that transplant-bound relapsed patients are treated with multi-drug regimens before harvest: 'General management' states that patients with high-risk/aggressive disease 'are generally treated with highly active three-or four-drug combinations to achieve maximal response' and that responders 'can then be considered for ASCT', and 'AUTOLOGOUS STEM CELL TRANSPLANTATION' notes that 'mobilization after reinduction using various mobilization regimen... is feasible' when a new stem cell collection is needed. However, no passage in our copy specifies a 3-4 month duration of pre-harvest therapy, nor does it state that the purpose of giving it before collection is to reduce tumour cell numbers in the bone marrow; the paper frames the three-drug approach as achieving maximal response in high-risk disease and explicitly leaves one- versus two- versus three-drug choice unsettled for indolent relapse. The quantitative and rationale components of the claim are therefore not attributable to this source. (LLM, conf=0.68)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low-dose dexamethasone (i.e., once weekly 40 mg dose) is associated with less dexamethasone-related toxicity than more intensive dosing scheme without compromising efficacy [48].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Partly supportedcites [48] Rajkumar, 2010, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial, Lancet Oncol. sourceExperimental — accuracy not yet measured
The Methods (Procedures; page unavailable) specify 40 mg dexamethasone once weekly in the low-dose arm. The Results and Discussion report less toxicity and no worse progression or survival outcomes with low-dose treatment, but the Results also find a significantly lower response rate after four cycles (68.3% versus 79%). Thus, “without compromising efficacy” is too broad, and the evidence is limited to treatment with lenalidomide in newly diagnosed myeloma. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
15 more claims · 1 with their cited sources checked
Create a free account to see all 66 claims and to verify the 18 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Multiple myeloma affects men more than women (3:2 ratio). 5,6”
From Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2024) · cites this paper as [5]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · cited 3×
“5 mg/L, and Stage II for all those in between [19].”
BackgroundInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210 · cited 1×
“The revised international staging system (RISS) combines elements of tumor burden (ISS) and disease biology [23].”
MethodBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · cited 1×
“Albeit weak, there is data suggesting that use of a proteasome inhibitor may abrogate the prognostic impact of at least some of these high-risk genetic markers [32].”
BackgroundDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“The recently approved monoclonal antibody, daratumumab, which targets CD38 (a re ceptor highly expr sed on myeloma cells), has become a favorite for later line induction regimens [35,36].”
BackgroundRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · cited 1×
“, once weekly 40 mg dose) is associated with less dexamethasone-related toxicity than more intensive dosing scheme without compromising efficacy [48].”
BackgroundMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908 · cited 1×
“, bortezomib, lenalidomide, dexamethasone) improved response rates, depth of response, progression-free survival, and overall survival compared with the then approved front-line regimen Rd (lenalidomide, dexamethasone) making a three-drug regimen the main stay of initial therapy for most patients with MM [25].”
BackgroundMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126397 · Cited by 778 · cited 1×
“Chimeric antigen receptor T cell therapy for the MM receptor BCMA is currently being investigated and has shown promise for refractory disease [49].”
BackgroundMcCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698 · cited 1×
“There is an increased risk for the development of both secondary hematologic and solid organ cancers, especially in post-transplant maintenance with lenalidomide [56].”
BackgroundGlobal Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631
Colmone, A., Amorim, M., Pontier, A. L., Wang, S., Jablonski, E., & Sipkins, D. A. (2008) · Science · doi:10.1126/science.1164390 · Cited by 541 · cited 3×
“The accumulation of the monoclonal antibody, Bence–Jones proteins, can precipitate in the urine resulting in kidney damage (usually type 2 renal tubular acidosis) and renal failure, and it can be seen in two-thirds of MM cases [2].”
BackgroundInfluentialKumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-395749 · Cited by 446 · cited 1×
“, patients with acute renal failure or those with increased thromboembolic risk) [26].”
BackgroundRacial disparities in incidence and outcome in multiple myeloma: a population-based study
Waxman, A. J., Mink, P. J., Devesa, S. S., Anderson, W. F., Weiss, B. M., Kristinsson, S. Y., McGlynn, K. A., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2010-07-298760 · Cited by 411 · cited 1×
“This discrepancy is over 3× among those below 50, showing that African Americans have a younger onset of disease, on average [13].”
BackgroundEfficacy and safety of once-weekly bortezomib in multiple myeloma patients
Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., et al. (2010) · Blood · doi:10.1182/blood-2010-07-294983 · Cited by 381
Updated Diagnostic Criteria and Staging System for Multiple Myeloma
Rajkumar, S. V. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159009 · Cited by 350
Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/leu.2017.329 · Cited by 305 · cited 2×
“Lastly, immunomodulators like lenalidomide, pomalidomide, and thalidomide are frequently used in triplet or quadruplet induction regimens and maintenance regimens [33,34].”
BackgroundRajkumar, S. V. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.63 · Cited by 289
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis
Waxman, A. J., Clasen, S., Hwang, W.-T., Garfall, A., Vogl, D. T., Carver, J., O’Quinn, R., Cohen, A. D., Stadtmauer, E. A., Ky, B., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4519 · Cited by 286 · cited 1×
“Cardiac complications, such as heart failure, chest pain, arrhythmias, and pulmonary hypertension, can be seen in patients when treated with carfilzomib [58,59].”
BackgroundRajkumar, S. V., Landgren, O., & Mateos, M.-V. (2015) · Blood · doi:10.1182/blood-2014-09-568899 · Cited by 269
Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group
Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia · doi:10.1038/leu.2015.356 · Cited by 258 · cited 2×
“Lastly, immunomodulators like lenalidomide, pomalidomide, and thalidomide are frequently used in triplet or quadruplet induction regimens and maintenance regimens [33,34].”
BackgroundKristinsson, S. Y., Pfeiffer, R. M., Björkholm, M., Goldin, L. R., Schulman, S., Blimark, C., Mellqvist, U.-H., Wahlin, A., Turesson, I., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2009-11-252072 · Cited by 255 · cited 1×
“thromboembolism compared to the general population [57].”
Frontline therapy of multiple myeloma
Moreau, P., Attal, M., & Facon, T. (2015) · Blood · doi:10.1182/blood-2014-09-568915 · Cited by 244 · cited 1×
“One of the most commonly used front-line triple therapies is bortezomib (a proteasome inhibitor), lenalidomide (an immunomodulator that downregulates inflammatory and proliferative cytokines), and dexamethasone (a longacting steroid), (called VRd after the tradenames Velcade, Revlimid, and Dexamethasone, respectively)…”
BackgroundLandgren, O., & Weiss, B. M. (2009) · Leukemia · doi:10.1038/leu.2009.134 · Cited by 231 · cited 1×
“Other studies have uncovered racial heterogeneity, such as a lower proportion of IgM MM or MGUS, among African Americans but have failed to explain the marked differences in disease risk [16].”
BackgroundCornell, R. F., Ky, B., Weiss, B. M., Dahm, C. N., Gupta, D. K., Du, L., Carver, J. R., Cohen, A. D., Engelhardt, B. G., Garfall, A. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00231 · Cited by 198 · cited 1×
“Cardiac complications, such as heart failure, chest pain, arrhythmias, and pulmonary hypertension, can be seen in patients when treated with carfilzomib [58,59].”
BackgroundUpdated Diagnostic Criteria and Staging System for Multiple Myeloma
Rajkumar, S. V. (2016) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbk_159009 · Cited by 179
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.21913 · Cited by 152
Central nervous system myelomatosis: review of the literature
Nieuwenhuizen, L., & Biesma, D. H. (2008) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00956.x · Cited by 147 · cited 1×
“Extramedullary disease can be seen in 5% of MM patients [37,38].”
BackgroundMultiple myeloma: 2012 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.22237 · Cited by 144 · cited 3×
“Outside of a clinical trial, VRd remains the preferred choice of initial chemotherapy for patients with high-risk MM who are not candidates for HCT [28,29].”
BackgroundResultGonsalves, W. I., Leung, N., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Dingli, D., Kapoor, P., Go, R. S., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.20 · Cited by 133 · cited 1×
“Up to 40% of the patients showed renal recovery when treated with proteasome inhibitors and immunomodulators and has shown to have a superior OS when compared to the non-responders [52].”
Bisphosphonates in multiple myeloma: a network meta-analysis
Mhaskar, R., Redzepovic, J., Wheatley, K., Clark, O. A. C., Miladinovic, B., Glasmacher, A., Kumar, A., & Djulbegovic, B. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003188.pub3 · Cited by 130
(2017) · PubMed · Cited by 129
Arnulf, B., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., van de Velde, H., Feng, H., Cakana, A., Deraedt, W., & Moreau, P. (2012) · Haematologica · doi:10.3324/haematol.2012.067793 · Cited by 127
Hari, P. N., Zhang, M.-J., Roy, V, Pérez, W. S., Bashey, A., To, L. B., Elfenbein, G., Freytes, C. O., Gale, R. P., Gibson, J., et al. (2009) · Leukemia · doi:10.1038/leu.2009.61 · Cited by 100
Multiple myeloma with central nervous system relapse
Egan, P. A., Elder, P. T., Deighan, W. I., O’Connor, S. J. M., & Alexander, H. D. (2020) · Haematologica · doi:10.3324/haematol.2020.248518 · Cited by 91 · cited 1×
“[41] provided a review of the current literature including the presentation, treatment, and survival data among patients with CNS involvement.”
BackgroundMerz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., Hielscher, T., Blau, I. W., Scheid, C., Hose, D., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.124347 · Cited by 73
Treatment and disease‐related complications in multiple myeloma: Implications for survivorship
Chakraborty, R., & Majhail, N. S. (2020) · American Journal of Hematology · doi:10.1002/ajh.25764 · Cited by 73 · cited 1×
“With the advancement in the treatment options, myeloma is more like a chronic disease and the goal of the therapy is to prevent end-organ damage and to attain diseasefree survival [50].”
BackgroundMGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology
Mateos, M., & Landgren, O. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_1 · Cited by 69
Baker, A., Braggio, E., Jacobus, S., Jung, S., Larson, D., Therneau, T., Dispenzieri, A., Van Wier, S. A., Ahmann, G., Levy, J., et al. (2013) · Blood · doi:10.1182/blood-2012-07-443606 · Cited by 66 · cited 1×
“A study that used genetic profiling and fluorescent in situ hybridization (FISH) testing to search for the genetic foundations of the greater risk among African Americans did not find significant results [15].”
BackgroundWaldenstrom macroglobulinemia: prognosis and management
Oza, A. M., & Rajkumar, S. V. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.28 · Cited by 58 · cited 1×
“, a B cell lymphoma as opposed to a plasma cell dyscrasia) and, thus, does not carry an increased risk for MM [6].”
BackgroundSchinasi, L. H., Brown, E. E., Camp, N. J., Wang, S. S., Hofmann, J. N., Chiu, B. C., Miligi, L., Beane Freeman, L. E., de Sanjose, S., Bernstein, L., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14199 · Cited by 57
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2018) · Blood · doi:10.1182/blood-2018-120737 · Cited by 50 · cited 1×
“Although OS data are immature, DRd has shown improved PFS when compared with Rd [27].”
ResultLeleu, X. P., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., Maisnar, V., Samoilova, O. S., Rosiñol, L., Langer, C., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25134 · Cited by 50
Extramedullary disease in plasma cell myeloma: the iceberg phenomenon
Wirk, B., Wingard, J. R., & Moreb, J. S. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.26 · Cited by 49 · cited 1×
“Extramedullary disease can be seen in 5% of MM patients [37,38].”
BackgroundMRI Features of Extramedullary Myeloma
Tirumani, S. H., Shinagare, A. B., Jagannathan, J. P., et al. (2014) · American Journal of Roentgenology · doi:10.2214/ajr.13.10856 · Cited by 38 · cited 3×
“Sci. 2021, 9, 3 12 of 14 Rd lenalidomide, dexamethasone VCd also called CyBorD bortezomib, cyclophosphamide, dexamethasone DRd daratumumab, lenalidomide, and dexamethasone KRd carfilzomib, lenalidomide, and dexamethasone RRMM relapsed/refractory multiple myeloma CNS central nervous system IMWG International Myeloma Wo…”
BackgroundInfluentialAtkin, C., Reddy‐Kolanu, V., Drayson, M. T., Sapey, E., & Richter, A. G. (2020) · British Journal of Haematology · doi:10.1111/bjh.16487 · Cited by 27 · cited 1×
“There were higher rates in those with chronic kidney disease heart failure, anemia, or leukocytosis [12].”
BackgroundBasali, D., Chakraborty, R., Rybicki, L., Rosko, N., Reed, J., Karam, M., Schlueter, K., Dysert, H., Kalaycio, M., & Valent, J. (2020) · British Journal of Haematology · doi:10.1111/bjh.16454 · Cited by 27 · cited 1×
“[40] has shown an overall response of approximately 78% during their experience with venetoclax-based regimens in ten RRMM patients who had a median of six prior lines of therapy.”
BackgroundRaje, N., Roodman, G. D., Willenbacher, W., Shimizu, K., García-Sanz, R., Terpos, E., Kennedy, L., Sabatelli, L., Intorcia, M., & Hechmati, G. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1445634 · Cited by 25 · cited 1×
“Other treatment considerations, including bisphosphonates, such as zoledronic acid, or bone-stimulating agents (BSAs), like denosumab, are recommended upon diagnosis in order to prevent or palliate lytic lesions and fractures [42,43].”
BackgroundReversible Dementia Due to Thalidomide Therapy for Multiple Myeloma
Morgan, A. E., Smith, W. K., & Levenson, J. L. (2003) · New England Journal of Medicine · doi:10.1056/nejm200305013481822 · Cited by 25 · cited 1×
“Cognitive deficits can be noted in patients treated with immunomodulators [54,55].”
BackgroundJurczyszyn, A., & Suska, A. (2019) · Reference Module in Biomedical Sciences · doi:10.1016/b978-0-12-801238-3.11412-6 · Cited by 13
Sheng, Z., Li, G., Li, B., Liu, Y., & Wang, L. (2017) · European Journal of Haematology · doi:10.1111/ejh.12877 · Cited by 10 · cited 2×
“KRd instead of VRd can be used as initial therapy in patients with t(4;14), t(14;16), t(14;20), and those with ≥2 high-risk abnormalities based on the results of phase 2 studies suggesting higher complete response (CR) rates and minimal residual disease negativity rates compared with historical results using VRd [28,3…”
ResultWeiss, B. M. (2013) · Blood · doi:10.1182/blood-2013-03-487215 · Cited by 9 · cited 1×
“Retrospective studies from single institutions as well as the South West Oncology Group (SWOG) found no differences in survival based on race [14].”
Background
Research works printed but not linked: 3
- Howlander, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2019). SEER Cancer Statistics Review 1975–2016.
- Vakiti, A., Padala, S.A., and Mewawalla, P. (2020, May 07). Myeloma Kidney, Available online: https://www.ncbi.nlm.nih.gov/books/NBK499952/.
- Vakiti, A., and Mewawalla, P. (2020, May 07). Malignancy-Related Hypercalcemia, Available online: https://www.ncbi.nlm.nih.gov/books/NBK482423/.
Cited by
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
Huang, J., Chan, S. C., Lok, V., Zhang, L., Lucero-Prisno, D. E., Xu, W., Zheng, Z.-J., Elcarte, E., Withers, M., & Wong, M. C. S. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00165-x · Cited by 229
Avet-Loiseau, H., Davies, F. E., Samur, M. K., Corre, J., D'Agostino, M., Kaiser, M. F., Raab, M. S., Weinhold, N., Gutierrez, N. C., Paiva, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01893 · Cited by 192
Approved CAR-T therapies have reproducible efficacy and safety in clinical practice
Vera, D. G., Waghela, H., Nuh, M., Pan, J. Z., & Lulla, P. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2378543 · Cited by 97
Metadata
- Authors
- Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H.
- Affiliations
- Augusta University (US)
- Allegheny Health Network (US)
- Sovah Health Martinsville (US)
- Corresponding author
- Padala, Sandeep Anand
- ORCID
- Venue
- Medical Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-20
- Volume
- 9
- Issue
- 1
- Pages
- 3
- ISSN
- 2076-3271 (ISSN-L)
- PMC
- PMC7838784
- OpenAlex
- W3125352349
- Semantic Scholar
- f98f43b63e68b1a4fa37ed1682b10b64d590a291
- Cited by
- 332
- References
- 56
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 87 · 2023: 66 · 2022: 38 · 2021: 5
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medical Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, incidence and mortality trends, risk factors, M protein, International Staging System, beta2-microglobulin, lactate dehydrogenase, chromosomal abnormalities, hematopoietic stem cell transplantation, bisphosphonates, skeletal-related events, relapsed multiple myeloma, daratumumab, proteasome inhibitors, immunomodulating agents, CAR T-cell therapy, BCMA, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma
- MeSH terms
- Immunomodulating Agents, Anemia, Humans, Hypercalcemia, Multiple Myeloma, Pain, Paraproteinemias, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.